XILIO THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.06 USD | -2.75% |
|
-3.64% | +92.73% |
| 04-19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
| 04-01 | Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2024 * | 7.5M 598M | Sales 2025 * | 18.75M 1.49B | Capitalization | 40.23M 3.21B |
|---|---|---|---|---|---|
| Net income 2024 * | -67M -5.34B | Net income 2025 * | -72M -5.74B | EV / Sales 2024 * | -20.8 x |
| Net cash position 2024 * | 196M 15.64B | Net cash position 2025 * | 302M 24.04B | EV / Sales 2025 * | -13.9 x |
| P/E ratio 2024 * |
-0.67
x | P/E ratio 2025 * |
-0.9
x | Employees | 73 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.09% |
More Fundamentals
* Assessed data
More news
Latest transcript on Xilio Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -2.75% | ||
| 1 week | -3.64% | ||
| Current month | -1.85% | ||
| 1 month | -30.72% | ||
| 3 months | +58.45% | ||
| 6 months | -49.52% | ||
| Current year | +92.73% |
1 week
0.95
1.15
1 month
0.951.63
Current year
0.501.93
1 year
0.493.30
3 years
0.4927.95
5 years
0.4927.95
10 years
0.4927.95
| Managers | Title | Age | Since |
|---|---|---|---|
René Russo
CEO | Chief Executive Officer | 49 | 21/05/19 |
Kevin Brennan
DFI | Director of Finance/CFO | 54 | - |
| Chief Tech/Sci/R&D Officer | - | 30/09/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Clancy
CHM | Chairman | 62 | 22/07/20 |
Daniel Curran
BRD | Director/Board Member | 57 | 30/11/20 |
Tomas Jan Heyman
BRD | Director/Board Member | 68 | 14/09/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 1.06 | -2.75% | 84 664 |
| 26/04/24 | 1.09 | +7.92% | 144,163 |
| 25/04/24 | 1.01 | -4.72% | 239,428 |
| 24/04/24 | 1.06 | +0.95% | 297,031 |
| 23/04/24 | 1.05 | -4.55% | 448,445 |
Delayed Quote Nasdaq, April 29, 2024 at 04:01 pm
More quotes
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.09
USD
Average target price
4.667
USD
Spread / Average Target
+328.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +92.73% | 40.23M | |
| +2.10% | 42.75B | |
| +47.58% | 41.61B | |
| +12.35% | 41.34B | |
| -12.36% | 26.59B | |
| +8.74% | 25.49B | |
| -23.35% | 18.12B | |
| +30.90% | 12.24B | |
| -1.68% | 11.76B | |
| +8.94% | 11B |
- Stock Market
- Equities
- XLO Stock
